Skip to main content
IMMUTEP Ltd logo

IMMUTEP Ltd — Investor Relations & Filings

Ticker · IMMP US Professional, scientific and technical activities
Filings indexed 711 across all filing types
Latest filing 2026-05-01 Foreign Filer Report
Country US United States of America
Listing US IMMP

About IMMUTEP Ltd

https://www.immutep.com/

Immutep Ltd. is a late clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. As a pioneer in its field, the company focuses on therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Immutep's diversified portfolio is designed to harness LAG-3 to either stimulate the immune response to fight cancer or modulate it to combat autoimmune diseases. Its lead product candidate is eftilagimod alfa, a soluble LAG-3 fusion protein under investigation in multiple oncology trials. The company maintains a pipeline of several clinical-stage assets targeting areas of high unmet medical need.

Recent filings

Filing Released Lang Actions
6-K - IMMUTEP Ltd (0001506184) (Filer)
Foreign Filer Report
2026-05-01 English
6-K
Foreign Filer Report
2025-12-22 English
6-K
Foreign Filer Report
2025-12-16 English
FORM 6-K
Foreign Filer Report
2025-12-09 English
FORM 6-K
Foreign Filer Report
2025-12-03 English
FORM 6-K
Foreign Filer Report
2025-11-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.